CN1593595A - Lung clearing preparation for treating respiratory virus infection diseases - Google Patents
Lung clearing preparation for treating respiratory virus infection diseases Download PDFInfo
- Publication number
- CN1593595A CN1593595A CNA2004100414056A CN200410041405A CN1593595A CN 1593595 A CN1593595 A CN 1593595A CN A2004100414056 A CNA2004100414056 A CN A2004100414056A CN 200410041405 A CN200410041405 A CN 200410041405A CN 1593595 A CN1593595 A CN 1593595A
- Authority
- CN
- China
- Prior art keywords
- lung
- group
- capsule
- antipyretics
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical preparation for clearing lung-heat which is prepared form Schizonepeta tenuifolia, honeysuckle flower, sweet wormwood, and artificial ox gallstone through the steps of sorting, rouging, watering and boiling,centrifugal filtrating, spray drying, dry method palletizing, spraying volatile oil, and charging cow-bezoar powder.
Description
One, technical field:
The present invention relates to technical field of Chinese medicines, specifically relating to the Chinese herbal medicine is that raw material prepares the medicine for the treatment of respiratory viral infection disease.
Two, background technology
Respiratory viral infection disease always is clinical commonly encountered diseases, frequently-occurring disease, and people's health even life in serious threat.Up to now, the respiratory tract disease to virus causes does not find specific short so far yet, and wherein most sick kind onsets are hurried, propagation is rapid, pathological lesion is serious, the state of an illness is complicated various, in case morbidity often causes very big harm.Spreading at world wide from November, 2002, and cause the SARS of lives and properties and economic development heavy losses, promptly is a typical example.And the human infection that the second half year, popular bird flu caused in the Asia in 2003 has also caused people's health and socio-economic development to seriously influence.Therefore, to the treatment of various respiratory viral infection diseases, be the focus of domestic and international medical research always.
The main clinical characteristics of respiratory viral infection disease is: performances such as generating heat, cough, cough up phlegm, the antiviral and the refrigeration function that mainly rely on medicine are treated.Therefore, from the existing technical merit in this field, aspect Western medicine, mainly contain antiviral drugs such as moroxydine hydrochloride, amantadine, ribavirin.But these medicines can only have certain effect to some virus, and certain side effect is arranged more.As: amantadine has neurotoxicity, can influence in the brain dopamine synthetic, discharge and picked-up, cause many moving, depressions, hallucination etc.The broad-spectrum antiviral medicament ribavirin can cause side effect such as hemolytic anemia, leukopenia, abnormal liver function and bilirubin rising.Zoopery shows, animal symptom such as can occur significantly becoming thin, weak after using.Simultaneously, though Western medicine has many effectively antipyretics, can only constantly stop the development of the state of an illness as anti symptom treatment usefulness, and some also there is bigger side effect.Western medicine is to develop corresponding vaccine at the main countermeasure of viral disease, but its development needs certain cycle on the one hand, often is unable to catch up with the needs of diseases prevention and treatment; On the other hand, for most of Respiroviruses, its variability is extremely strong, so concerning respiratory viral disease, even certain virus has been developed vaccine, and being another virus probably, popular thereafter disease causes, so the appearance of new Strain with countless changes in the reality is not often dealt with in the development of vaccine.The treatment by Chinese herbs respiratory viral infection disease has certain advantage all the time, can remarkable at short notice relief of symptoms.From present present Research, relevant report and existing Chinese patent medicine are all not rare, but wherein exist obviously not enough.Mainly show: this type of research often is confined to heat and toxic materials clearing away medicine on prescription, the double compatibility that presss from both sides the dialectical and square medicine of syndrome of disease is all paid little attention to, especially the treatment that the common cold and heat of such disease fold or cold and heat are unclear is lacked the side's of treatment medicine targetedly, thereby limited the scope of application of the various respiratory virus infections of utilization treatment by Chinese herbs greatly.
Three, summary of the invention
1, goal of the invention
The object of the present invention is to provide a kind of medicine of evident in efficacy, widely applicable, treatment respiratory viral infection disease that cold and heat are taken into account.
2, technical scheme
A kind of treatment respiratory viral infection disease lung-clearing preparation, formed by following materials of weight proportions medicine:
Herba Schizonepetae 8～15 grams, Flos Lonicerae 8～15 grams, Herba Artemisiae Annuae 8～15 grams, artificial Calculus Bovis's 0.2～1.0 gram.
The prescription meaning: Flos Lonicerae in the side, sweet in flavor and cold in property, the merit of tool heat-clearing and toxic substances removing is arrogated to oneself the heat that lung heat clearing is defended, and light weight gas perfume (or spice), has the diffusing merit of a surname concurrently, for controlling the principal agent that epidemic febrile disease is defended at lung from the beginning of, heresy, with being monarch drug.
Herba Schizonepetae, the little bitterness tepor of acrid in the mouth can expelling pathogenic wind from the body surface, evacuates pathogenic heat, and tepor and not dry is with being ministerial drug.Flos Lonicerae is joined Herba Schizonepetae, has acted on the marrow that Wu brings up logical Lonicerae and Forsythiae Powder compatibility, joins the fragrance of Herba Schizonepetae with the hot cold of Flos Lonicerae, plays the merit of heat radiation detoxifcation altogether; Using medicines of both cold and hot natures simultaneously has also enlarged the our scope of application.Calculus Bovis, sweet-bitter flavor is cool in nature, and the merit of stronger heat-clearing and toxic substances removing is arranged, and Fang Zhongyong is a messenger drug, and one can strengthen the strength of honeysuckle flower for reducing fever, detoxicating, and two can bring into play the effect of " blocking in advance ", stop the change of disease inwards of the evil poison of pathogenic wind-warm.Herba Artemisiae Annuae, the little suffering of bitter in the mouth is cold in nature, and its gas fragrance can heat clearing away, ward off dirty, removing dampness, is messenger drug.Flos Lonicerae, Herba Schizonepetae, Herba Artemisiae Annuae be the product of light weight gas perfume (or spice) all, can ward off dirty, removing dampness, remove pestilence.We sincerely abide by the old maxim " the treatment part of the body cavity above the diaphragm housing the heart and lungs such as plumage, non-light erectile problem " of treatment epidemic febrile disease, and medication is agile and flavor is thin, the new theory that " blocks in advance " in conjunction with science of epidemic febrile disease of Chinese medicine again, and using medicines of both cold and hot natures simultaneously is intended to removing summer-heat and evacuates the evil poison of pathogenic wind-warm that part of the body cavity above the diaphragm housing the heart and lungs lung is defended.Full method degree is rigorous, and compatibility is precise and appropriate, and the medicine letter is imitated specially, has heat-clearing and toxic substances removing, dispelling wind and heat pathogens, wards off the dirty effect of removing pestilence.
The Herba Schizonepetae, Herba Artemisiae Annuae that take by weighing above-mentioned weight be through arrangement, roguing, removes old stalk, is cut into the segment of one-inch size respectively; Flos Lonicerae is roguing after putting in order, together drops in the extraction pot, adds water and makes it the medical material submergence, place 30min, connect volatile oil gathering-device (selecting for use), be heated to and boil than water heavy volatile oil and than all collectable model of the light volatile oil of water, and little insulation 30min that boils,, collect decocting liquid and volatile oil for the first time; And then add water and cross the medical material surface, be heated to and boil, and little insulation 30min that boils, decocting liquid and volatile oil for the second time collected; Merge 2 times decocting liquid, leave standstill to room temperature, centrifugal filtration, spray drying, dry granulation sprays into volatile oil, adds the artificial bezoar powder, promptly gets lung-clearing preparation.
Above-mentioned lung-clearing preparation only needs to add suitable adjuvant and promptly can be made into solid orally ingestibles such as granule, tablet and capsule.
The application of a kind of lung-clearing preparation in preparation treatment respiratory viral infection disease medicine.
This medicine shows that through pharmacological tests capsule of antipyretics for lung compares with similar Western medicine, have good antiviral and regulate the effect of immunologic function, can alleviate the pulmonary lesion that causes because of influenza infection, reduce the lung index, the mortality rate that can reduce due to illness poison infection and cause, and have tangible antiinflammatory, resolve phlegm effect.Because capsule of antipyretics for lung has the same usefulness of cold and heat medicine on prescription, be particularly useful for respiratory viral infection disease early, the cold and heat treatment of folder, the unclear syndrome of cold and heat of holding concurrently in mid-term.
3, beneficial effect
It is few to treat the selectable Chinese patent medicine kind of respiratory tract infectious disease at present clinically, and under card feelings complexity, cold and heat were held concurrently assorted situation, medication was had too many difficulties to cope with especially, and lung heat clearing medicine of the present invention is compared with existing Chinese patent medicine, has the following advantages:
(1), capsule of antipyretics for lung has the characteristics of cold and heat medicine with usefulness on prescription, be particularly useful for respiratory viral infection disease early, the cold and heat treatment of folder, the unclear syndrome of cold and heat of holding concurrently in mid-term.And hot temperature is dispersed and hot cool removing summer-heat two class crude drug reasonable compatibilities, and synergism can produce than the even more ideal therapeutic effect of single class heat and toxic materials clearing away medicine.
(2) capsule of antipyretics for lung is compared with similar Western medicine, has good antiviral and regulates the effect of immunologic function, and the chase after thermal effect similar to Western medicine antipyretic-antalgic agent commonly used arranged.
(3) capsule of antipyretics for lung can alleviate the pulmonary lesion that influenza infection causes, reduces the lung index, can reduce the mortality rate that causes because of influenza infection.
(4) capsule of antipyretics for lung has tangible antiinflammatory, resolve phlegm effect.
Four, the specific embodiment
The composition of embodiment 1, lung-clearing preparation
Herba Schizonepetae 10g, Flos Lonicerae 12g, Herba Artemisiae Annuae 10g, artificial Calculus Bovis 0.5g
The preparation of embodiment 2, capsule of antipyretics for lung
The Herba Schizonepetae, Herba Artemisiae Annuae that take by weighing above-mentioned weight be through arrangement, roguing, removes old stalk, is cut into the segment of one-inch size respectively; Flos Lonicerae is roguing after putting in order, drops in the extraction pot, adds water and makes it the medical material submergence, place 30min, connect volatile oil gathering-device (selecting for use), be heated to and boil than water heavy volatile oil and than all collectable model of the light volatile oil of water, and little insulation 30min that boils,, collect decocting liquid and volatile oil for the first time; Add water and cross the medical material surface, be heated to and boil, and little insulation 30min that boils, decocting liquid and volatile oil for the second time collected; Merge 2 times decocting liquid, leave standstill to room temperature, centrifugal filtration, spray drying, dry granulation sprays into volatile oil, adds the artificial bezoar powder, and the encapsulating capsule is made capsule of antipyretics for lung then.
The antivirus action of embodiment 3, capsule of antipyretics for lung
(1) capsule of antipyretics for lung is to the influence of influenza virus Lung Index of mice infected by Influenza virus
1. experiment material
1.1 medicine and reagent
Capsule of antipyretics for lung, Nanjing University of Traditional Chinese Medicine's epidemic febrile disease institute provides specification: 0.2g crude drug/ml.
Ribavirin injection, Yancheng, Jiangsu pharmaceutical Co. Ltd produces, lot number is 20023003, with distilled water diluting to 0.0065g/ml.
Ether, the Nanjing first chemical reagent factory produces, lot number 021010785.
1.2 laboratory animal
The ICR mice, body weight 20 ± 2g, male and female half and half, totally 72.Nanjing Medical University's Experimental Animal Center provides, production licence number SCXK (Soviet Union) 2002-031.
1.3 viral seed culture of viruses
Influenza virus Mus adapted strain FM1, Nanjing University of Traditional Chinese Medicine's epidemic febrile disease institute is preserved, and hemagglutinative titer is 1: 640, and LD50 is 10-4.68.
2. experimental technique
2.1 animal grouping is divided into normal control group, virus model group (negative control), ribavirin group (positive control), capsule of antipyretics for lung medicine group at random with animal, totally 4 groups, 12 every group, male and female half and half.
2.2 medication and dosage capsule of antipyretics for lung group give medicine and irritate stomach, dosage is 10g/kg/d, and virus model group and normal control group are irritated stomach with normal saline, irritates the stomach amount and is 0.2ml/10g, 2 times on the one.Every mouse peritoneal injection of ribavirin group ribavirin 0.13g/kg/d, 2 times on the one, successive administration 7 days.
2.3 after the modeling method administration for the first time, mice is slightly anaesthetized, splashes into the viral liquid 50ul of 2LD50 from nasal cavity with ether.The normal control group is dripped the normal saline with equivalent.
2.4 observation index
Get lung and weigh, calculate the lung index as follows:
Lung index=mouse lung weight/mice body weight * 100
After the administration 7 days, all put to death mice, take by weighing body weight.Open the thoracic cavity and take out lungs, extract tissues such as trachea, hilar lymph node, blot lungs surface blood stasis, take by weighing lungs weight, calculate the lung index according to lung weight and weighing machine with filter paper.
3 results
Experimental result shows, the capsule of antipyretics for lung medicine can reduce the lung index that viral infection causes and increase, and statistics has significant difference.See Table 1.
Table 1 capsule of antipyretics for lung is to the influence of influenza virus Lung Index of mice infected by Influenza virus (X ± s)
Grouping number of animals (n) dosage (g/kg) lung index
Normal control group 12 isometric(al)s 0.706 ± 0.106
*
Virus model group 12 isometric(al)s 1.7 ± 0.492
Ribavirin group 12 0.13 1.234 ± 0.357
*
No. two medicine groups 12 10.0 1.166 ± 0.385 of lung heat clearing
*
Compare with the virus model group,
*P＜0.05;
*P＜0.01.
4 conclusions
Capsule of antipyretics for lung can alleviate the pulmonary lesion that influenza infection causes, reduces the lung index.
(2) capsule of antipyretics for lung is to the influence of the dead protective rate of influenza virus infecting mouse
1. experiment material
1.1 medicine and reagent are the same.
1.2 animal ICR cleaning level mouse inbred lines, body weight 15 ± 2g, male and female half and half, totally 96.Nanjing Medical University's Experimental Animal Center provides.
1.3 viral influenza virus Mus adapted strain FM1, Nanjing University of Traditional Chinese Medicine's Chinese medicine antiviral laboratory is preserved.Recording its hemagglutinative titer after Embryo Gallus domesticus goes down to posterity is 1: 640, and LD50 is 10-4.68.
2. experimental technique
2.1 the animal group technology is the same.
2.2 medication and dosage capsule of antipyretics for lung group give medicine and irritate stomach, dosage is 10g/kg/d, and virus model group and normal control group are irritated stomach with normal saline, irritates the stomach amount and is 0.2ml/10g, 2 times on the one.Every mouse peritoneal injection of ribavirin group ribavirin 0.13g/kg/d, 2 times on the one, successive administration 7 days.
2.4 after the modeling method administration for the first time, mice is slightly anaesthetized, splashes into the viral liquid 50ul of 20LD50 from nasal cavity with ether.
2.3 observation index
Day by day observe the dead mouse situation, totally 14 days.Calculate mortality rate as follows:
Mortality rate=dead number of mice/experiment mice * 100%
Calculate dead protective rate as follows: dead protective rate=(matched group mortality rate-experimental group mortality rate) * 100%
3 results
Experimental result shows that capsule of antipyretics for lung can improve the dead protective rate of influenza infection mice, and statistics has significant difference.See Table 2.
Table 2 capsule of antipyretics for lung medicine is to the influence of the dead protective rate of influenza virus infecting mouse
Grouping number of animals (n) death toll (n) the survival dead protective rate of number (n) mortality rate (%) (%)
Normal control group 24 0 24 0
*
Virus control group 24 20 4 83.33
Ribavirin group 24 12 12 50
*33.33
No. two medicine groups 24 3 21 12.5 of lung heat clearing
*70.83
Compare with the virus model group,
*P＜0.05;
*P＜0.01.
4 conclusions
Capsule of antipyretics for lung has certain protective role to the influenza virus infecting mouse, can reduce the mortality rate that influenza infection causes.
(3) capsule of antipyretics for lung is to the influence of Sendai virus infecting mouse pulmonary lesion
1. experiment material
1.1 medicine and reagent are the same.
1.2 animal ICR kind mice, body weight 20 ± 2g, male and female half and half.Nanjing University of Traditional Chinese Medicine's Experimental Animal Center provides.
1.3 the strain of viral paramyxovirus celestial platform, Yao of Nanjing Medical University Kun professor is so kind as to give, and recording its hemagglutinative titer after Embryo Gallus domesticus goes down to posterity is 1: 1280.
2. experimental technique
2.1 the animal grouping is the same.
2.2 medication and dosage capsule of antipyretics for lung group give medicine and irritate stomach, dosage is 10g/kg/d, and virus model group and normal control group are irritated stomach with normal saline, irritates the stomach amount and is 0.2ml/10g, 2 times on the one.Every mouse peritoneal injection of ribavirin group ribavirin 0.13g/kg/d, 2 times on the one, successive administration 6 days.
2.3 after the modeling method administration for the first time, mice is slightly anaesthetized, splashes into virus stock solution used 50ul from nasal cavity with ether.The normal control group is dripped the normal saline with equivalent.
2.4 observation index
Get lung and weigh, calculate the lung index as follows.
Lung index=mouse lung weight/mice body weight * 100
After the administration 6 days, all put to death mice, take by weighing body weight.Open the thoracic cavity and take out lungs, extract tissues such as trachea, hilar lymph node, blot lungs surface blood stasis, take by weighing lungs weight, calculate the lung index according to lung weight and weighing machine with filter paper.
3 results
Experimental result shows that capsule of antipyretics for lung can reduce the lung index of Sendai virus infecting mouse, and its statistics has significant difference.See Table 3.
Table 3 capsule of antipyretics for lung is to the influence of Sendai virus Lung Index of mice infected by Influenza virus (X ± s)
Grouping number of animals (n) dosage (g/kg) lung index
Normal control group 12 isometric(al)s 0.706 ± 0.106
*
Virus model group 12 isometric(al)s 2.196 ± 0.167
Ribavirin group 12 0.13 1.159 ± 0.37
*
Capsule of antipyretics for lung group 12 10.0 1.752 ± 0.651
*
Compare with the virus model group,
*P＜0.05;
*P＜0.01.
4 conclusions
Capsule of antipyretics for lung can alleviate Sendai virus and infect the pulmonary lesion that causes, reduces the lung index.
(4) capsule of antipyretics for lung is to the influence of the dead protective rate of Sendai virus infecting mouse
1. experiment material
1.1 medicine and reagent are the same.
1.2 animal ICR cleaning level mouse inbred lines, body weight 15 ± 1g, male and female half and half.Nanjing Medical University's Experimental Animal Center provides.
1.3 virus
The strain of paramyxovirus celestial platform, Yao of Nanjing Medical University Kun professor is so kind as to give, and recording its hemagglutinative titer after Embryo Gallus domesticus goes down to posterity is 1: 1280.
2. experimental technique
2.1 the animal grouping is the same.
2.2 medication and dosage capsule of antipyretics for lung group give medicine and irritate stomach, dosage is 10g/kg/d, and virus model group and normal control group are irritated stomach with normal saline, irritates the stomach amount and is 0.2ml/10g, 2 times on the one.Every mouse peritoneal injection of ribavirin group ribavirin 0.13g/kg/d, 2 times on the one, successive administration 6 days.
2.4 after the modeling method administration for the first time, mice is slightly anaesthetized, splashes into virus stock solution used 50ul from nasal cavity with ether.The normal control group is dripped the normal saline with equivalent.
2.4 observation index
Day by day observe the dead mouse situation, totally 7 days, and perform record.Calculate mortality rate as follows:
Mortality rate=dead number of mice/experiment mice * 100%
Calculate dead protective rate as follows: dead protective rate=(matched group mortality rate-experimental group mortality rate) * 100%
2.5 statistical analysis technique is the same.
3 results
Experimental result shows that capsule of antipyretics for lung can improve the dead protective rate of Sendai virus infecting mouse, and statistics has significant difference.See Table 4.
Table 4 capsule of antipyretics for lung is to the influence of the dead protective rate of Sendai virus infecting mouse
Grouping number of animals (n) death toll (n) the survival dead protective rate of number (n) mortality rate (%) (%)
Normal control group 16 0 16 0
*
Virus control group 16 16 0 100
Ribavirin group 16 2 14 12.5
*87.5
Capsule of antipyretics for lung group 16 11 5 68.75
*31.25
Compare with the virus model group,
*P＜0.05;
*P＜0.01.
4 conclusions
Capsule of antipyretics for lung has certain protective role to the influenza virus infecting mouse, can reduce the mortality rate that influenza infection causes.
The refrigeration function of embodiment 4, capsule of antipyretics for lung
(1) capsule of antipyretics for lung is to the influence of fever in rabbits effect
1 experiment purpose is observed the influence of capsule of antipyretics for lung to fever in rabbits effect due to the escherichia coli endotoxin.
2 materials and method
2.1 medicine and pyrogenicity agent
Capsule of antipyretics for lung, specification 0.4 crude drug/ml is by Nanjing University of Traditional Chinese Medicine's epidemic febrile disease Research Institute.
Paracetamol tablets (acetaminophen), specification 0.5g/ sheet, lot number 030810, metal and stone pharmacy head factory in Shantou is produced, and the time spent is made into the suspension of desired concn with distilled water.
Escherichia coli endotoxin, Ecoli O127 B6 is produced by U.S. Sigma company, is made into 1ug/ml solution with normal saline, puts 4 ℃ of refrigerators and preserves standby.
2.2 the laboratory animal Japan large ear rabbit, body weight 1.8～2.5kg, male and female are regardless of, and Nanjing kind rabbit field boundary provides.
2.3 the experiment equipment electronic clinical thermometer, Dalian, Omron company limited is produced.
2.4 method
Examination of basal body temperature: rabbit is surveyed the anus temperature every day 2 times after the laboratory adaptability is fed 2 days, continuous 2 days, choose the normal person of body temperature and experimentize, and with the average of 4 anus temperature as basal body temperature.
Grouping: will be selected in rabbit and be divided into model group, acetaminophen group and capsule of antipyretics for lung group at random after by the body temperature layering.
Modeling and administration: each organizes rabbit gastric infusion respectively, and the acetaminophen group is 0.047g/kg, and the capsule of antipyretics for lung group is 10.4g/kg, and model group is given the isometric(al) normal saline.Injected through the pre-warm escherichia coli endotoxin aqueous solution of 37 ℃ of water-baths by auricular vein immediately after the administration, dosage is 0.4ug/kg.As above method repeat administration 1 time after 1 hour.
Body temperature observation: 0.5h, 1h, 2h, 3h, 4h, 5h respectively survey the anus temperature 1 time behind counteracting toxic substances, are that baseline is drawn temperature curve with the basal body temperature, calculate 5 hours body temperature index of Response (TRI5).
3 results
Experimental result shows that capsule of antipyretics for lung can obviously reduce the rabbit body temperature that causes behind the counteracting toxic substances and raise, and there were significant differences with model group.See Table 5.
Table 5 capsule of antipyretics for lung is to the influence of body temperature index of Response (X ± SD)
Group number of animals (n) dosage (g/kg) TRI
5
Model group 8 isometric(al) normal saline 24.6 ± 2.76
Acetaminophen 8 0.045 9.66 ± 4.90
*
Capsule of antipyretics for lung group 8 10.4 14.61 ± 9.10
*
Annotate:
*P＜0.01
4 conclusions
The heating that capsule of antipyretics for lung causes escherichia coli endotoxin has certain antipyretic effect.
(2), the influence to rat fever due to the dry yeast of capsule of antipyretics for lung
1. experiment purpose utilizes dry yeast to duplicate the rat fever model, observes the antipyretic effect of capsule of antipyretics for lung.
2. experiment material
2.1 medicine and pyrogenicity agent
Capsule of antipyretics for lung, specification: 0.2g crude drug/ml, Nanjing University of Traditional Chinese Medicine's epidemic febrile disease Research Institute.
Paracetamol tablets (acetaminophen), specification: the 0.5g/ sheet, lot number 030810, metal and stone pharmacy head factory in Shantou is produced, and the time spent is made into the suspension of 2.25mg/ml with distilled water.
Dry yeast, specification 10g/ bag, lot number 20040614, Hubei Angel Yeast company limited is produced, and faces with before taking by weighing dry yeast 15g, puts in the mortar, adds distilled water gradually and grinds to hanging slurry uniformly, and last standardize solution is 100ml, is made into 15% suspension.
2.2 30 of animal SD cleaning level rats, body weight 200g ± 20g, male and female half and half, Chinese Academy of Sciences's Shanghai Experimental Animal Center provides.
2.3 the apparatus electronic thermometer, Dalian, Omron company limited is produced.
3. experimental technique
3.1 the mensuration of rat basal body temperature
Rat is after laboratory environment adapts to 3 days, and every day is with temperature instrumentation anus temperature 1 time, and continuous 4 days, selection standard was poor＜± 0.3 animal is for experiment usefulness, the average of 4 anus temperature as basal body temperature.
3.2 preliminary experiment
Get 3 of rats, subcutaneous injection 15% sterilised yeast suspension in the back, dosage is 1.5g/kg, later every diaphragm 1h surveys rat temperature once, observes the variation of temperature curve, determines that correct delivery time is 6h behind the injection yeast.
3.3 model preparation and grouping
The subcutaneous injection 15% dry yeast suspension of all selected rat backs, dosage is 1.5g/kg, surveys body temperature in injection back 6h, and the rat of 0.8 ℃ of fervescence is divided into 3 groups at random, is respectively model group, acetaminophen group and capsule of antipyretics for lung group, 10 every group, male and female half and half.
3.4 medication
Model prepare successfully and grouping after be gastric infusion once.Capsule of antipyretics for lung group dosage is 4g/kg, and acetaminophen group dosage is 0.045g/kg for using medicine liquid irrigation stomach, dosage, and model group is irritated stomach with isometric normal saline.1.5h back repeat administration once.
3.4 observation index
1/2h, 1h, 2h, 3h, 4h, 5h respectively survey rat anus temperature once after the administration, calculate the body temperature net added value as follows, and record body temperature and the body temperature net added value is drawn temperature curve according to experiment.
The body temperature net added value (℃)=experiment records body temperature-basal body temperature.
4 results
Half an hour after the medication, acetaminophen group body temperature begins to descend, continue to drop to administration for the first time after 3 hours body temperature rise once more.The capsule of antipyretics for lung group began cooling in 2 hours after the administration first time, though cooling extent is obvious not as the acetaminophen group, the persistent period is longer, can be maintained to after the administration for the first time 5 hours.Experimental result shows, the acetaminophen cooling rapidly, the body temperature fall is big, but the persistent period is shorter relatively, though and the capsule of antipyretics for lung cooling rate is slow slightly, the body temperature fall not as acetaminophen obvious, but body temperature decline longer duration and stablizing, two groups of body temperature descend with model group relatively, significant difference is all arranged, see Table 6, table 7.
Table 6. capsule of antipyretics for lung is to influence (X ± s) (n=10) of rat fever due to the dry yeast
Body temperature (℃)
Group
Time after the administration (h)
6h after the basal body temperature modeling
0.5 1 2 3 4 5
Model group 38.1 ± 0.3 39.6 ± 0.4 39.7 ± 0.4 39.9 ± 0.3 39.7 ± 0.4 39.8 ± 0.3 39.7 ± 0.5 39.5 ± 0.6
Acetaminophen group 38.2 ± 0.4 39.7 ± 0.3 38.6 ± 0.2**38.8 ± 0.5**38.5 ± 1.0**38.8 ± 0.8**39.4 ± 0.2 39.7 ± 0.3
Capsule of antipyretics for lung group 38.2 ± 0.3 39.6 ± 0.3 39.7 ± 0.4 39.8 ± 0.2 39.1 ± 0.8*, 39.1 ± 0.8*, 39.0 ± 0.7**39.0 ± 0.6*
Compare * P＜0.05 with model group; * P＜0.01.
Table 7. capsule of antipyretics for lung has a net increase of influence (X ± s) (n=10) that grows to rat fever due to the dry yeast
Group body temperature net added value (℃)
Time after the administration (h)
6h after the modeling
0.5 1 2 3 4 5
Model group 1.4 ± 0.4 1.6 ± 0.5 1.8 ± 0.4 1.6 ± 0.5 1.6 ± 0.5 1.6 ± 0.6 1.4 ± 0.7
Acetaminophen group 1.5 ± 0.4 0.4 ± 0.5**0.6 ± 0.7**0.3 ± 1.3**0.7 ± 1.2**1.2 ± 0.5 1.5 ± 0.5
Capsule of antipyretics for lung group 1.4 ± 0.3 1.5 ± 0.4 1.6 ± 0.3 0.9 ± 0.7*, 0.8 ± 0.9*, 0.8 ± 0.8**0.8 ± 0.7*
Compare * P＜0.05 with model group; * P＜0.01.
5. the heating that dry yeast is caused of conclusion capsule of antipyretics for lung medicine has certain inhibitory action.
Embodiment 5, capsule of antipyretics for lung are to regulating the effect of immunologic function
1. experiment purpose
By observing the influence of capsule of antipyretics for lung, study its effect to the body non-specific immunity to the Turnover of Mouse Peritoneal Macrophages phagocytic function.
2. experiment material
2.1 medicine
Capsule of antipyretics for lung, specification: 0.2g crude drug/ml, Nanjing University of Traditional Chinese Medicine's epidemic febrile disease Research Institute.
Positive control drug: Radix Astragali oral liquid, lot number 020118-2, Jiangsu TCM Hospital produces, and is mixed with the solution that contains stock solution 0.104ml/ml with distilled water.
2.2 animal
The ICR mice, body weight 20 ± 2g, male and female half and half, totally 30.China Medicine University's Experimental Animal Center provides.1 of cock.
2.3 apparatus and reagent
Microscope, autoclave sterilizer, centrifuge, incubator, microscope slide etc.
Alsever ' s liquid: glucose 2.08g, sodium citrate 0.80g, citric acid 0.055g, sodium chloride 0.42g, adding distil water filter back 10 pounds of 15min autoclavings to 100ml.
4% auspicious-Ji's Albert'stain Albert liquid: 2 of reagent 1 and reagent one bottle (50ml), Nanjing is built up bio-engineering research and is produced.
3. experimental technique
3.1 grouping divides physiology saline group, Radix Astragali oral liquid group and capsule of antipyretics for lung medicine group, 10 every group, male and female half and half.
3.2 dosage and method
Capsule of antipyretics for lung group medicine liquid irrigation stomach, dosage are 0.25ml/10g, and normal saline group and Radix Astragali oral liquid group are then irritated with isometric normal saline and Radix Astragali oral liquid.Administration every day 2 times, administration 5 days.
3.3 detection index
Press the chicken erythrocyte suspension of literature method preparation 5%.The chicken red blood cell of mouse peritoneal injection 5%, dosage is 1ml/10g.The animal broken end is let out blood execution after 5 hours, cuts off skin of abdomen, injects normal saline 2ml through the abdominal cavity, and soft abdominal part 1min cuts off stomach wall, extracts abdominal cavity washing liquid 1ml out, drips to be applied on the clean slide every 0.2ml.Be placed on then in the aluminium lunch box that is lined with wet gauze, place 37 ℃ of incubators to hatch 30min.After incubation finishes, microscope slide is dropped into rinsing in the normal saline, to remove not attached cell, dry, with the fixing 5min of methanol solution, behind reuse 4% auspicious-Ji's Albert'stain Albert liquid dyeing 3min, with the distilled water rinsing, dry, the chicken red blood cell number of being engulfed in 200 macrophages of every counting under oily mirror, calculate phagocytic percentage and phagocytic index as follows:
4 results
Capsule of antipyretics for lung can improve phagocytic percentage and the phagocytic index of Turnover of Mouse Peritoneal Macrophages to chicken red blood cell, and statistical significance is arranged, and shows that capsule of antipyretics for lung can improve the mice non-specific immunity.The results are shown in Table 8 and table 9.
Table 8. capsule of antipyretics for lung is to the influence of Turnover of Mouse Peritoneal Macrophages phagocytic percentage
Packet samples is counted phagocytic percentage (X ± s)
Normal saline group 10 15.65 ± 4.65
Radix Astragali oral liquid group 10 26.25 ± 10.51*
Capsule of antipyretics for lung 10 25.44 ± 9.12*
Compare with the normal saline group,
*P＜0.05.
Table 9. capsule of antipyretics for lung is to the influence of Turnover of Mouse Peritoneal Macrophages phagocytic index
Packet samples is counted phagocytic index (X ± s)
Normal saline group 10 0.1855 ± 0.0447
Radix Astragali oral liquid group 10 0.3506 ± 0.1427**
Capsule of antipyretics for lung 10 0.3163 ± 0.0467*
Compare with the normal saline group,
*P＜0.05,
*P＜0.01.
The antiinflammatory action of embodiment 6, capsule of antipyretics for lung
1. experiment purpose
Stimulate auricular concha with proinflammatory agent, cause auricular concha local skin generation swelling, observe and measure the weight of capsule of antipyretics for lung and matched group auricular concha then, and compare the difference of its swelling rate, thus the antiinflammatory action of research capsule of antipyretics for lung.
2. experiment material
2.1 medicine
Capsule of antipyretics for lung, specification: 0.2g crude drug/ml, Nanjing University of Traditional Chinese Medicine's epidemic febrile disease Research Institute.
Positive control drug: meticorten, lot number 20000901, Nanjing second pharmaceutical factory produces, and is made into the suspension of 0.16mg/ml.
2.2 animal ICR mice, body weight 20 ± 2g, male and female half and half, totally 36.China Medicine University's Experimental Animal Center provides.
2.3 apparatus and reagent
Apparatus: card punch, precision balance, pipettor etc.
Proinflammatory agent: dimethylbenzene (chemical pure), chemical reagent factory in Nanjing produces, lot number 20020901.Be made into the concentration of 0.3mg/ml.
3. experimental technique
3.1 grouping divides physiology saline group, meticorten group and capsule of antipyretics for lung medicine group, 12 every group, male and female half and half.
3.2 dosage and method
Capsule of antipyretics for lung group medicine liquid irrigation stomach, dosage are 0.25ml/10g, and normal saline group and meticorten group are then irritated with isometric normal saline and meticorten suspension.Administration every day 2 times, administration 4 days.
3.3 detection index
Dimethylbenzene is applied to two sides, mouse right ear front and back, the about 0.1ml of every Mus, left ear compares.Put to death animal behind the 30min, cut two ears, lay round auricle at the same position of two ears respectively, weigh with precision balance with 9mm diameter card punch along the auricle baseline.Calculate the swelling rate of Mice Auricle according to formula.
Swelling rate (%)=(auris dextra-left ear) ÷ left side ear * 100%.
4 results
Capsule of antipyretics for lung can reduce dimethylbenzene induced mice auricular concha swelling rate, compares with the normal saline group, and significant difference is arranged, and shows that capsule of antipyretics for lung has antiinflammatory action, sees Table 10.
The influence of table 10. capsule of antipyretics for lung xylol induced mice auricular concha swelling rate
Packet samples is counted swelling rate (X ± s)
Normal saline group 12 1.000 ± 0.273
Meticorten group 12 0.681 ± 0.327*
Capsule of antipyretics for lung 12 0.677 ± 0.328*
Compare with the normal saline group,
*P＜0.05.
The cough-relieving of embodiment 7, capsule of antipyretics for lung, resolve phlegm effect
(1), the antitussive action of capsule of antipyretics for lung
1. experiment purpose
By causing mouse cough model with ammonia, the antitussive action of research capsule of antipyretics for lung is for clinical application provides reference.
2. experiment material
2.1 medicine
Capsule of antipyretics for lung, specification: 0.2g crude drug/ml, Nanjing University of Traditional Chinese Medicine's epidemic febrile disease Research Institute.
Positive control drug: carbetapentane citrate, specification: 25mg carbetapentane citrate/sheet, medicine Group Co.,Ltd in Suzhou produces, and lot number: 020118-2 grinds and is superfine powder, crosses 80 mesh sieves, is mixed with the carbetapentane citrate suspension of 0.457mg/ml with CMC-Na.
2.2 animal ICR mice, body weight 20 ± 2g, male and female half and half, totally 36.China Medicine University's Experimental Animal Center provides.
2.3 apparatus and reagent
Apparatus: ultrasound atomizer, stopwatch.
Ammonia: lot number 02033157, chemical reagent one factory in Nanjing produces, and is made into 25% concentration during experiment with distilled water.
3. experimental technique
3.1 grouping divides physiology saline group, carbetapentane citrate group and capsule of antipyretics for lung medicine group, 12 every group, male and female half and half.
3.2 dosage and method
Capsule of antipyretics for lung group medicine liquid irrigation stomach, dosage are 0.25ml/10g, and normal saline group and carbetapentane citrate group are then irritated with isometric normal saline and carbetapentane citrate suspension.Administration every day 2 times, administration 4 days.
3.3 detection index
Mice is put into inverted 250ml beaker, constitute a confined space, ultrasonic atomizatio is gone into 25% ammonia in this space, for the time 20 seconds, observe mouse cough incubation period and 2min cough number of times, average after the two people numeration.
4 results
Capsule of antipyretics for lung and normal saline group compare, and cough latent period slightly increases, and 2min cough number of times reduces to some extent, but does not have significant difference, illustrates that the capsule of antipyretics for lung antitussive action is not obvious.The results are shown in Table 11 and table 12.
Table 11. capsule of antipyretics for lung is to the preclinical influence of mouse cough
Packet samples is counted cough latent period (X ± s second)
Normal saline group 12 34.36 ± 10.45
Carbetapentane citrate group 12 36.75 ± 7.56
Capsule of antipyretics for lung 12 35.17 ± 8.43
Table 12. capsule of antipyretics for lung is to the influence of mice 2min cough number of times
Packet samples is counted 2min cough number of times (X ± s)
Normal saline group 12 66.64 ± 13.25
Carbetapentane citrate group 12 52.85 ± 11.72*
Capsule of antipyretics for lung 12 61.33 ± 11.54
Compare * P＜0.01 with the normal saline group.
(2), the resolve phlegm effect of capsule of antipyretics for lung
1. experiment purpose
By giving the phenol red phenol red excretion of trachea of observing then of injected in mice, the resolve phlegm effect of research capsule of antipyretics for lung is for clinical application provides reference.
2. experiment material
2.1 medicine
Capsule of antipyretics for lung, specification: 0.2g crude drug/ml, Nanjing University of Traditional Chinese Medicine's epidemic febrile disease Research Institute.
Positive control drug: ammonium chloride, licence numbering XK 13-2010282197II, China Medicine (Group) Shanghai Chemical Reagent Co., produces, and is mixed with the solution of 0.02g/ml during experiment.
2.2 animal ICR mice, body weight 20 ± 2g, male and female half and half, totally 36.China Medicine University's Experimental Animal Center provides.
2.3 apparatus and reagent
654 type spectrophotometers, medical apparatus factory in Shanghai produces.
Phenol red, lot number 951124, reagent three factories in Shanghai produce, and are made into the suspension of 5g/dl with normal saline.
Sodium hydroxide, lot number 970106, chemical reagent factory in Nanjing is made into the sodium hydroxide solution of 1N with distilled water.
3. experimental technique
3.1 grouping divides physiology saline group, ammonium chloride group and capsule of antipyretics for lung medicine group, 12 every group, male and female half and half.
3.2 dosage and method
Capsule of antipyretics for lung group medicine liquid irrigation stomach, dosage are 0.25ml/10g, and normal saline group and ammonium chloride group are then irritated with isometric normal saline and ammonium chloride solution.Administration every day 2 times, administration 4 days.
3.3 detection index
The phenol red suspension of every mouse peritoneal injection 0.1ml (5mg)/10g, put to death after half an hour, peel off the trachea surrounding tissue, cut one section trachea down to the trachea bifurcation from thyroid cartilage, put into the test tube that fills the 2ml normal saline, add the 0.1ml sodium hydroxide again, survey the OD value with the 546nm wavelength with 654 type spectrophotometers.With phenol red work one standard curve,, compare with each group more earlier according to the phenol red content of curve calculation (ug/ml).
3 results
Capsule of antipyretics for lung and normal saline group compare, and the phenol red excretion amount of trachea significantly raises, and significant difference is arranged, and illustrates that capsule of antipyretics for lung has obvious resolve phlegm effect.The results are shown in Table 13.
Table 13. capsule of antipyretics for lung is to the influence of the phenol red excretion amount of mice trachea section (X ± s)
The grouping number of animals phenol red excretion amount of trachea (ug/ml)
Normal saline group 12 0.965 ± 0.488
Ammonium chloride group 12 2.056 ± 0.734*
Capsule of antipyretics for lung 12 2.006 ± 0.949*
Compare * P＜0.01 with the normal saline group.
Claims (4)
1, a kind of lung-clearing preparation is characterized in that being made up of following materials of weight proportions medicine: Herba Schizonepetae 8-15 gram, Flos Lonicerae 8-15 gram, Herba Artemisiae Annuae 8-15 gram, artificial Calculus Bovis 0.2-1.0 gram.
2, lung-clearing preparation according to claim 1 is characterized in that adding an amount of adjuvant and can be made into solid orally ingestible.
3, lung-clearing preparation according to claim 2 is characterized in that described preparation is a capsule.
4, the application of lung-clearing preparation in preparation treatment respiratory viral infection disease medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100414056A CN1287811C (en) | 2004-07-16 | 2004-07-16 | Lung clearing preparation for treating respiratory virus infection diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100414056A CN1287811C (en) | 2004-07-16 | 2004-07-16 | Lung clearing preparation for treating respiratory virus infection diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593595A true CN1593595A (en) | 2005-03-16 |
| CN1287811C CN1287811C (en) | 2006-12-06 |
Family
ID=34665040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100414056A Expired - Fee Related CN1287811C (en) | 2004-07-16 | 2004-07-16 | Lung clearing preparation for treating respiratory virus infection diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1287811C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100560102C (en) * | 2006-03-27 | 2009-11-18 | 江苏康缘药业股份有限公司 | A kind of Chinese medicine composition for the treatment of cough due to lung-heat, hyperpyrexia |
| CN104306660A (en) * | 2014-10-10 | 2015-01-28 | 天津瑞贝特科技发展有限公司 | Traditional Chinese medicine composition for treating viral diseases of poultry and preparation method of traditional Chinese medicine composition |
-
2004
- 2004-07-16 CN CNB2004100414056A patent/CN1287811C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100560102C (en) * | 2006-03-27 | 2009-11-18 | 江苏康缘药业股份有限公司 | A kind of Chinese medicine composition for the treatment of cough due to lung-heat, hyperpyrexia |
| CN104306660A (en) * | 2014-10-10 | 2015-01-28 | 天津瑞贝特科技发展有限公司 | Traditional Chinese medicine composition for treating viral diseases of poultry and preparation method of traditional Chinese medicine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1287811C (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1309399C (en) | Compound 'Shuanghuanglian' preparation and preparing process thereof | |
| CN1850249A (en) | Composition with function of relieving cough and calming asthma and preparing method | |
| CN1212856C (en) | Medicine composition for treating sphagitis and preparing method thereof | |
| CN1605335A (en) | Antivirus dihydromyricetin and myricetin containing pharmaceutical composition | |
| CN1593595A (en) | Lung clearing preparation for treating respiratory virus infection diseases | |
| CN1813780A (en) | Chinese medicine composition for treating cold fever and liver damage and its preparing method | |
| CN1879706A (en) | 'Shuang Huang Lian' dispersible tablet and preparation method thereof | |
| CN101032544A (en) | Medicine composition of compound honeysuckle organic acid and the preparing method of the agent thereof | |
| CN1602886A (en) | Pharmaceutical compositions and its application | |
| CN1596939A (en) | Chinese patent drug for treating heart brain blood vessel disease and its preparation method | |
| CN1709436A (en) | Yinzhihuang tablet of oriental wormwood, cape jasmine and baicalin, and its preparing and detecting method | |
| CN1579455A (en) | Composition of traditional Chinese medicine for large intestine hygropyretic disease and its preparation method | |
| CN1190223C (en) | Recipe of Chinese medicine with treating and health care functions | |
| CN1554407A (en) | Medicine for clearing away lung-heat, eliminating phaegn, reliveing cough and asthma and its preparing method | |
| CN1579531A (en) | Medicinal composition for treating anemopyretic cold and its preparation method | |
| CN1857609A (en) | Chinese medicine composition with nourishing health function and its preparing method | |
| CN1287835C (en) | Pharmaceutical composition for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1636584A (en) | Medicine composition for treating upper respiratory tract infection and its prepn process | |
| CN1714842A (en) | Chinese medicine composition for smoothing liver-gallbladder and clearing heat and detoxicating and its preparing method | |
| CN1136851C (en) | Medicine for curing bronchial asthma and asthmatic chronic bronchitis and its preparing process | |
| CN1586604A (en) | Zedoary injection preparation and its preparing method | |
| CN1650993A (en) | Antivirus Chinese medicine compound preparation and its preparation method | |
| CN1169569C (en) | Composite medicine for treating mastoplasia and its preparing process | |
| CN1572298A (en) | Arbidol containing compound preparation | |
| CN1181872C (en) | Medicine for acute pulmonary infection and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061206 Termination date: 20140716 |
|
| EXPY | Termination of patent right or utility model |